Oncolytic virus startup Calidi secures $25M toward Series B round

Paul Schloesser

Associate Editor

Calidi Biotherapeutics, a San Diego biotech working on developing allogeneic cell delivery of oncolytic viruses, said Friday that investors have committed $25 million to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Oncolytic virus startup Calidi secures $25M toward Series B round

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

On­colyt­ic virus start­up Ca­li­di se­cures $25M to­ward Se­ries B round

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Oncolytic virus startup Calidi secures $25M toward Series B round